Comparative Pharmacology
Head-to-head clinical analysis: IMPLANON versus NIKKI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPLANON versus NIKKI.
IMPLANON vs NIKKI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10%
Category C
Category C
Contraceptive
Contraceptive